Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV
or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI)
experienced, with documented resistance to more than one PI. Determine pharmacokinetic data
in this co-infected population and potential utility of using therapeutic drug monitoring
(TDM) in improving efficacy outcomes.